-
Choroidal thickening with serous retinal detachment in BRAF/MEK inhibitor-induced uveitis : Elektronski vir : a case reportKiraly, Peter, medicina ...Immune checkpoint inhibitors have revolutionized the treatment of patients with unresectable metastatic malignant melanoma. In addition to systemic side effects, several usually mild ocular adverse ... effects have been reported. We report a case of rarely reported vision-threatening bilateral panuveitis with serous retinal detachment, thickened choroid, and chorioretinal folds associated with dabrafenib and trametinib targeted therapy for B-Raf proto-oncogene serine/threonine kinase (BRAF) mutant metastatic cutaneous melanoma. CASE SUMMARY A 59-year-old female patient with metastatic melanoma treated with dabrafenib and trametinib presented with blurry vision and central scotoma lasting for 3 d in both eyes. Clinical examination and multimodal imaging revealed inflammatory cells in the anterior chamber, mild vitritis, bullous multiple serous retinal detachments, and chorioretinal folds in both eyes. Treatment with dabrafenib and trametinib was suspended, and the patient was treated with topical and intravenous corticosteroids followed by oral corticosteroid treatment with a tapering schedule. One and a half months after the disease onset, ocular morphological and functional improvement was noted. Due to the metastatic melanoma dissemination, BRAF/mitogen-activated protein kinase inhibitors were reintroduced and some mild ocular adverse effects reappeared, which later subsided after receiving oral corticosteroids. CONCLUSION Patients on combination therapy with dabrafenib and trametinib may rarely develop severe bilateral panuveitis with a good prognosis. Further studies have to establish potential usefulness of ophthalmological examination for asymptomatic patients. Furthermore, appropriate guidelines for managing panuveitis associated with dabrafenib and trametinib should be established.Vir: World journal of clinical cases [Elektronski vir]. - ISSN 2307-8960 (Vol. 10, iss. 19, Jul. 2022, str. 6536-6542)Vrsta gradiva - e-članekLeto - 2022Jezik - angleškiCOBISS.SI-ID - 113203971
Avtor
Kiraly, Peter, medicina |
Lavrič, Alenka, oftamologija |
Vidović Valentinčič, Nataša |
Jaki Mekjavić, Polona |
Urbančič, Mojca, 1967- |
Ocvirk, Janja |
Mesti, Tanja
Teme
metastatski melanom |
kemoterapija |
zaviralci BRAF/MEK |
neželeni učinki na očeh |
metastatic melanoma treatment |
chemotherapy |
BRAF/MEK inhibitors |
ocular adverse effects
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|---|
Kiraly, Peter, medicina | |
Lavrič, Alenka, oftamologija | 28293 |
Vidović Valentinčič, Nataša | 20708 |
Jaki Mekjavić, Polona | 11537 |
Urbančič, Mojca, 1967- | 25125 |
Ocvirk, Janja | 13541 |
Mesti, Tanja | 32614 |
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Obvestilo
Gesla v Splošnem geslovniku COBISS
Izbira mesta prevzema
Mesto prevzema | Status gradiva | Rezervacija |
---|
Prosimo, počakajte trenutek.